COMMUNIQUÉS West-GlobeNewswire

Novonesis delivered 8% organic sales growth in the first nine months of 2025
06/11/2025
Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine [...]
Privia Health Reports Third Quarter 2025 Financial Results
06/11/2025
Very Strong Third Quarter and Year-to-Date Performance Across the Business Net Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q’24 Implemented Providers +13.1% and Practice Collections +27.1% compared to 3Q’24 FY [...]
LifeStance Reports Third Quarter 2025 Results
06/11/2025
SCOTTSDALE, Ariz., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third [...]
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
06/11/2025
4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up [...]
Reviv Celebrates Over 20,000 Customers Worldwide
06/11/2025
A Global Phenomenon in Addressing TMJ Disorder and Related Health Issues Wilmington, DE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Reviv , a pioneering direct-to-consumer wellness brand, proudly announces a significant [...]
Enovis Announces Third Quarter 2025 Results
06/11/2025
Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October [...]
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
06/11/2025
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
06/11/2025
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome [...]
Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook
06/11/2025
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary GAAP [...]
Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook
06/11/2025
Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year period Third Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year period Adjusted EBITDA for Q3 [...]
Teleflex Announces Quarterly Dividend
06/11/2025
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The [...]
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
06/11/2025
- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of [...]
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
06/11/2025
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase [...]
Pow.Bio, Bühler, and ATV Technologies Announce Major Advancement in Continuous Biomanufacturing with 3,000-Liter Scale Success
06/11/2025
ALAMEDA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pow.Bio, the pioneer in continuous biomanufacturing, Bühler Group, the global solutions provider for food, feed, and advanced materials, and ATV Technologies, the [...]
WeightWatchers Announces Third Quarter 2025 Results
06/11/2025
End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net [...]
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
06/11/2025
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori [...]
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
06/11/2025
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to [...]
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
06/11/2025
Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership team with key [...]
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
06/11/2025
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for planned adaptive [...]

Pages